Trials / Terminated
TerminatedNCT06304636
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Descartes-15 | Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2025-04-14
- Completion
- 2025-11-13
- First posted
- 2024-03-12
- Last updated
- 2025-11-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06304636. Inclusion in this directory is not an endorsement.